The Novasep-PharmaZell Group has announced a €7.3 million investment for its Mourenx site (southwestern France), as part of a larger project supported by the "France Relance" Plan, to create a multipurpose pilot workshop within one of its production units.
This new industrial tool will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used to treat cancer.
This investment includes an upgrade of two existing 2000 L reactors to optimise their versatility and functionality, together with the addition of a new 1500 L reactor and Hastelloy filter-dryer.
The new multipurpose workshop will be equipped to produce batches ranging from 30 to 100 kg for clinical trials, process validation and commercial production of APIs for targeted therapies, with a focus on HPAPIs.
"This major project to modernise and expand the Mourenx site demonstrates our new Group's determination to pursue the strategy of industrial investments that we have been successfully deploying for several years”, says Jean Bléhaut, President of the CDMO Business Unit.
"This is a clear and practical answer for our pharmaceutical customers, who face growing challenges to secure supply chains in the field of healthcare products, and particularly APIs.”
"Creating this unit is an opportunity to diversify the Mourenx site's activity with a new state-of-the-art production tool that improves our capacity for handling highly potent therapeutic products", adds Patrick Suescun, Mourenx Site Director. "This will clearly be beneficial to our clients and their patients, as well as to our local teams, who will be working with the best equipment to fulfil our commitments."
Since the completion of the Novasep-PharmaZell merger, announced on April 7, the new Group's strategy is focused on offering its customers greater competitiveness, secure supply chains, and full support throughout the lifecycle of their products.